Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Disease Progression
Female
Humans
Receptor, ErbB-2
Safety
Trastuzumab
authors with profiles
Melody A Cobleigh